If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 483.76% and ...